Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
News|Articles|August 6, 2025
OncLive’s July EMA Regulatory Recap: Key EU Approvals in Oncology
Author(s)Courtney Flaherty
Fact checked by: Chris Ryan
Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in July 2025.
Advertisement
Advertisement
Stay up-to-date with the latest regulatory milestones shaping cancer care across Europe. Below is your guide to all oncologic therapies approved by the European Commission (EC) in July 2025, including the pivotal clinical data behind each decision. Read on to learn more!
Related to this article
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
The top 5 OncLive TV videos of the week cover insights in essential thrombocythemia, CML, pancreatic cancer, myelofibrosis, and chronic neutropenia.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.
T-DXd plus pertuzumab was approved in the European Union as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
Advertisement
Advertisement